Impact of Barostimulation on Hemodynamics in Adults With Heart Failure

This study evaluates the effects of the implantation and adjustment of the CVRx Barostim device in adult patients with heart failure with reduced ejection fraction who are receiving maximally tolerated doses of guideline directed medical and device therapies. The study aims to assess how therapy using this device affects heart function, symptoms, and exercise capacity, with particular focus on how the device affects blood flow and heart pressures during exercise. Information from this study may help inform patient selection and device management in patients with heart failure.

NCT Number	NCT07335510
Lead Sponsor	Columbia University Collaborators: CVRx, Inc.
Conditions	HFrEF - Heart Failure With Reduced Ejection Fraction
Enrollment	58 participants
Start Date	2026-03-30
Primary Completion	2027-12 (estimated)
Study Completion	2028-03 (estimated)
Updated on ClinicalTrials.gov	2026-06-29